Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 4,271 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ADM Clear all
Completed Phase 2 Interventional Results available

Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery

NCT00956930
View directory record Official record
Conditions
Liver Cancer
Interventions
yttrium Y 90 glass microspheres, Doxorubicin
Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Nov 14, 2026, 5:54 AM EST
Completed Phase 4 Interventional Results available

Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study

NCT01668667
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GSK1838262 600 mg, GSK1838262 450 mg, GSK1838262 300 mg, GSK1838262 Placebo match
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
42
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Nov 14, 2026, 5:54 AM EST
Active, not recruiting Phase 2Phase 3 Interventional Results available

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02839707
View directory record Official record
Conditions
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma
Interventions
Atezolizumab, Bevacizumab, Computed Tomography, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
907
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 574 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2026 · Synced Nov 14, 2026, 5:54 AM EST
Completed Phase 2 Interventional

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

NCT01156753
View directory record Official record
Conditions
Breast Cancer
Interventions
CDX-011, "Investigator's Choice" chemotherapy
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
24
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Fatigue Reduction Diet

NCT01902745
View directory record Official record
Conditions
Chronic Fatigue
Interventions
Social Cognitive Theory
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Nov 14, 2026, 5:54 AM EST
Recruiting Phase 4 Interventional

NextGen - Clinical Implication of Next Generation Sequencing

NCT05206500
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Antibiotic, Next Gen
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Nov 14, 2026, 5:54 AM EST
Active, not recruiting Phase 2 Interventional

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Interventions
Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, Rituximab, Tafasitamab, Vincristine, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Biospecimen Collection
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional

Study for Treatment of Cancer in Children With Ataxia-telangiectasia

NCT00187057
View directory record Official record
Conditions
Ataxia-Telangiectasia
Interventions
vinblastine, vincristine, prednisone, daunorubicin, doxorubicin, methotrexate, cyclophosphamide, L-asparaginase, etoposide, cytarabine, mercaptopurine, dexamethasone, procarbazine, chemotherapy, intrathecal chemotherapy, steroid therapy
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 10 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2015 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Facial Wrinkles

NCT03831477
View directory record Official record
Conditions
Rhytides, Wrinkle
Interventions
Venus Viva
Device
Lead sponsor
Venus Concept
Industry
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional Results available

Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI

NCT02057081
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Posttraumatic Stress Disorders, Depression
Interventions
Multifamily Group for mTBI for Couples, Group Health Education (GHE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional Results available

Multi-hospital Electronic Decision Support for Drug-associated Acute Kidney Injury

NCT06264752
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Level A, Level B, Passive Alert
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Altoona, Pennsylvania • Farrell, Pennsylvania • McKeesport, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 14, 2026, 5:54 AM EST
Completed Phase 4 Interventional Results available

Baseline Oral Health Study: UnCoVer the Connections to General Health

NCT04954313
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Type 2
Interventions
Subgingival chlorhexidine irrigation, Dental Supplies, Periodonal Treatment
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
786 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Nov 14, 2026, 5:54 AM EST
Completed No phase listed Observational

Resiliency in Older Adults Undergoing Bone Marrow Transplant

NCT04188678
View directory record Official record
Conditions
Leukemia, Lymphoma, Blood Cancer, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Non-Hodgkins Lymphoma
Interventions
Bone Marrow Transplant (BMT)
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
60 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers

NCT01829308
View directory record Official record
Conditions
Alcohol-induced Disorders, Drug Users, Tobacco Use Disorder
Interventions
The brief interventions are delivered by behavioral health counselors (Specialist), The brief interventions are delivered by the primary care provider (Generalist)
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Nov 14, 2026, 5:54 AM EST
Completed No phase listed Observational

The Genetics of Respiratory Failure in Bronchiolitis

NCT01271491
View directory record Official record
Conditions
Bronchiolitis
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
Up to 2 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 14, 2026, 5:54 AM EST
Terminated Phase 1Phase 2 Interventional Results available

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04517435
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
ME-401, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
Deepa Jagadeesh
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Nov 14, 2026, 5:54 AM EST
Completed Phase 1 Interventional

Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate

NCT02361125
View directory record Official record
Conditions
Fatigue
Interventions
Methylphenidate, Fatigue Evaluations
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Nov 14, 2026, 5:54 AM EST
Active, not recruiting Not applicable Interventional Results available

Fetoscopic NEOX Cord 1K® Spina Bifida Repair

NCT04243889
View directory record Official record
Conditions
Spina Bifida, Myelomeningocele, Myeloschisis
Interventions
NEOX Cord 1K
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 14, 2026, 5:54 AM EST
Terminated Phase 2 Interventional Results available

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

NCT01779050
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Doxorubicin, Trastuzumab, Cyclophosphamide, Paclitaxel, Epirubicin, Docetaxel, Carboplatin, Fluorouracil
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional

Fatigue in Breast Cancer: A Behavioral Sleep Intervention

NCT00572416
View directory record Official record
Conditions
Breast Cancer
Interventions
Individual Sleep Promotion Plan, Healthy Eating Control
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Nov 14, 2026, 5:54 AM EST
Active, not recruiting Phase 2 Interventional Results available

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

NCT03233347
View directory record Official record
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Dacarbazine, Doxorubicin, Laboratory Biomarker Analysis, Nivolumab, Vinblastine
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 60 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Duarte, California • Rochester, Minnesota • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 14, 2026, 5:54 AM EST
Completed Phase 1Phase 2 Interventional Results available

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00440726
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Nov 14, 2026, 5:54 AM EST
Completed Not applicable Interventional Results available

Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy

NCT04299425
View directory record Official record
Conditions
Parathyroid Adenoma, Parathyroid Neoplasms, Parathyroid Hyperplasia, Parathyroid Cancer, Hypercalcemia, Primary Hyperparathyroidism
Interventions
NIRAF Detection Technology
Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Nov 14, 2026, 5:54 AM EST
Completed Phase 2 Interventional Results available

Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

NCT00581776
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Nov 14, 2026, 5:54 AM EST